Voluntary withdrawal of Imfinzi indication in advanced bladder cancer in the US
22 February 2021 07:00 GMT Voluntary withdrawal of Imfinzi indicationin advanced bladder cancer in the US AstraZeneca today announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer. This decision was made in consultation with the Food and Drug Administration (FDA). In May 2017, Imfinzi was granted accelerated approval in the US based on promising tumour response rates and duration of response data from Study 1108, a Phase I/II trial that evaluated the safety and